Research peptides · For laboratory and scientific research in vitro · Not medications · Not approved for consumption · Adults only (18+)
Cagrilintide (long-acting amylin)
In plain language
Long-acting amylin analog developed by Novo Nordisk. Combined with Semaglutide (CagriSema) shows −22% body weight in Phase 3 REDEFINE-1 (2025).
For researchers
Activates amylin receptors (AMY1-3), reduces gastric emptying and signals satiety in the area postrema of the brainstem. Synergizes with through complementary satiety pathways.
Scientific literature
Information about Cagrilintide is based on published scientific research and is intended for research purposes. Not medical advice.
Products related to this peptide are for in vitro laboratory research only. Not approved for human consumption.
Other peptides